UBE2D4 is an E2 ubiquitin-conjugating enzyme that catalyzes covalent ubiquitin attachment to substrate proteins, with preference for Lys-11 and Lys-48-linked polyubiquitination 1. The enzyme facilitates p53 ubiquitination and proteasomal degradation through interaction with E3 ligases including CHIP and MDM2 2, 3. Disease relevance centers on environmental toxicology and cancer. Cadmium and arsenic exposure suppress UBE2D4 expression via inhibition of transcription factors YY1 and FOXF1, leading to p53 accumulation and p53-dependent apoptosis in renal proximal tubular cells 4, 2, 5. This mechanism is critical for heavy metal-induced renal toxicity, though the p53-UBE2D4 pathway shows tissue-specific regulation 6. Conversely, in glioma, UBE2D4 is upregulated through YY1-mediated transcriptional activation and promotes tumor progression by enhancing p53 degradation, thereby accelerating G2/M cell cycle progression and enabling evasion of p53-dependent tumor suppression 3. UBE2D4 upregulation in glioma correlates with poor patient survival, positioning it as a potential therapeutic target. These opposing roles—protective through p53 stabilization in toxicology but oncogenic through p53 suppression in cancer—reflect context-dependent pathway regulation.